- Dalal Street Corner: Market ends flat even as FII selling nears exhaustion; what should investors do on Friday?
- Exclusive: June GST collections estimated at Rs 1.37-1.39 lakh cr, sources tell Zee Business ahead of announcement on 1 July
- Eknath Shinde sworn in as 30th Chief Minister of Maharashtra, Fadnavis becomes Deputy CM
- Gold Price Today: Weaker Rupee to hold yellow metal slide domestically, amid strengthening Dollar; analyst suggests strategy
- Monsoon session of Parliament to begin on July 18; to end on August 12
Aurobindo Pharma to recall 80 lots of blood pressure medicine Valsartan in the U.S.
The impurity N-Nitrosodiethylamine (NDEA) was detected in quantities above the acceptable limit in certain tablets containing valsartan, the FDA said.
A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration.
The impurity N-Nitrosodiethylamine (NDEA) was detected in quantities above the acceptable limit in certain tablets containing valsartan, the FDA said.
The announcement comes a month after Mylan NV said it will recall all lots of its blood pressure medicines containing valsartan, an angiotensin II receptor blocker, after global health authorities clamped down on the drug.
The health regulator said it will continue to investigate and test all angiotensin II receptor blockers for the presence of NDEA and another probable carcinogen N-nitrosodimethylamine.
In October last year, the FDA halted imports of drug ingredients or medicines containing ingredients produced at a factory of a Chinese bulk manufacturer of valsartan, Zhejiang Huahai Pharmaceuticals.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
07:58 am